Table 3.
Postoperative Complications and Other Outcomes.
| Group I (n = 26) | Group II (n = 20) | p-Value | |
|---|---|---|---|
| Postop complication | 3 (11.5%) | 2 (10.0%) | 0.627 1 |
| IOP increase | 0 | 2 | |
| Vitreous hemorrhage | 1 | 0 | |
| Fibrovascular membrane proliferation | 2 | 0 | |
| 12-month Postop hemoglobin A1c (%) | 7.89 ± 1.76 | 6.94 ± 0.33 | 0.328 2 |
| IVB injections after SO removal (n, %) | 6 (23.1%) | 0 (0.0%) | 0.025 1 |
Values are presented as the mean ± standard deviation or a number (%). Group I received an SO tamponade without IVB injection; group II received an SO tamponade with IVB injection; IOP, intraocular pressure; Postop, postoperative; SO, silicone oil; IVB, intravitreal bevacizumab. 1 Fisher’s exact test; 2 Mann–Whitney U-test.